Salbutamol

AstraZeneca unveils latest research across key respiratory and immune-mediated diseases at ATS 2024 showcasing strength of its broad pipeline and portfolio

Retrieved on: 
Wednesday, May 1, 2024
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Mortality, FDA, Risk, ICS, Death, Weight loss, Growth, Gastrointestinal tract, Rash, TSLP, Formoterol, Biopharmaceutical, AstraZeneca, LABA, Inflammation, Salbutamol, Skin, Tezepelumab, Approval, EGPA, AMG, Allergy, Polyp (medicine), Bronchitis, Chronic obstructive pulmonary disease, Patient, Eosinophilic, Sinusitis, Rheumatology, Heart, Atmosphere, Fatigue, Immunology, Budesonide, Lung, Chronic pain, Asthma, COPD, Gastroenterology, Emphysema, Disease, Science, Conditional sentence, Dermatology, Pharmaceutical industry

In addition, we are also collaborating with AstraZeneca on AMG104/AZD8630, an inhaled anti-TSLP compound currently in development for asthma.

Key Points: 
  • In addition, we are also collaborating with AstraZeneca on AMG104/AZD8630, an inhaled anti-TSLP compound currently in development for asthma.
  • Respiratory & Immunology, part of BioPharmaceuticals, is one of AstraZeneca’s main disease areas and is a key growth driver for the Company.
  • With common pathways and underlying disease drivers across respiratory and immunology, AstraZeneca is following the science from chronic lung diseases to immunology-driven disease areas.
  • AstraZeneca’s ambition in Respiratory & Immunology is to achieve disease modification and durable remission for millions of patients worldwide.

AstraZeneca caps patient out-of-pocket costs at $35 per month for its US inhaled respiratory portfolio

Retrieved on: 
Monday, March 18, 2024
Biotechnology, Medical Devices, Health, Pharmaceutical, Health Insurance, Diabetes, Blood pressure, Depression, Arrhythmia, Hypokalemia, ICS, Anaphylaxis, Angioedema, Congress, Moyamoya disease, AstraZeneca, MAOI, Hyperthyroidism, Risk, ECG, Incidence, Headache, Immunosuppression, Patient, QT interval, Chronic obstructive pulmonary disease, Inhalation, Chickenpox, Research, Budesonide, System, Liver, Cough, Rash, Infection, Salbutamol, Water, Cataract, Adrenal gland, Measles, Safety, Bronchospasm, COPD, Glaucoma, Use, Catherine Disher, Fatality, Monoamine oxidase inhibitor, Hypertension, Medicine, Pharmaceutical industry

AstraZeneca announced it will expand the savings programs for its entire US inhaled respiratory portfolio, helping eligible patients pay no more than $35 per month for their medicine.

Key Points: 
  • AstraZeneca announced it will expand the savings programs for its entire US inhaled respiratory portfolio, helping eligible patients pay no more than $35 per month for their medicine.
  • We remain dedicated to addressing the need for affordability of our medicines, but the system is complex and we cannot do it alone.
  • The Company will continue to provide discounts and rebates off the list price to help patients afford its inhaled respiratory medicines.
  • AstraZeneca remains dedicated to transforming patient outcomes, while ensuring access and affordability of our innovative medicines.

FTC Files Amicus Brief in Asthma Inhaler Patent Dispute

Retrieved on: 
Tuesday, April 2, 2024
The Orange Book, GSK plc, AstraZeneca, District court, Boehringer Ingelheim, Social media, Salbutamol, Policy, News, Blog, Motion, Judgement, Orange Book, Commission, Patent, FDA, Federal Trade Commission, Food, FTC

Improper Orange Book listings can harm competition by delaying the entry of cheaper generic products, according to the FTC’s brief.

Key Points: 
  • Improper Orange Book listings can harm competition by delaying the entry of cheaper generic products, according to the FTC’s brief.
  • The FTC’s amicus brief relates to a case brought by Teva against drugmaker Amneal after Amneal sought FDA approval to bring a generic version of asthma inhaler ProAir HFA to market.
  • Teva sued Amneal for patent infringement, arguing that Amneal’s patents infringe on Teva’s ProAir HFA patents.
  • The FTC’s amicus brief was filed in the U.S. District Court for the District of New Jersey.

AIRSUPRA® (albuterol/budesonide) now available as the first and only FDA-approved anti-inflammatory rescue option for asthma

Retrieved on: 
Monday, January 22, 2024
FDA, Health, Managed Care, Clinical Trials, Pharmaceutical, Biotechnology, Ageing, Budesonide, Potassium, Allergy, Swelling, Mouth, Patient, Cataract, Pneumonia, Rash, Approval, Wheeze, Multimedia, Cough, Face, Kidney, Hypokalemia, ICS, International, Fungal infection, Catherine Disher, Medicine, Risk, Immunology, Global Initiative for Asthma, Water, Periodic breathing, Disease, Inflammation, Tongue, OCS, Common, Glaucoma, Red, Treatment, Itch, Chest pain, Salbutamol, Headache, Cardiovascular disease, US6, Pharmaceutical industry

In MANDALA, AIRSUPRA was superior to albuterol in reducing the risk of severe asthma exacerbations in patients with moderate to severe asthma.

Key Points: 
  • In MANDALA, AIRSUPRA was superior to albuterol in reducing the risk of severe asthma exacerbations in patients with moderate to severe asthma.
  • In DENALI, AIRSUPRA had a similar onset of bronchodilation compared to albuterol in patients with mild to moderate asthma.2
    The approach to treating asthma symptoms with rescue has changed.
  • The 2023 Global Initiative for Asthma (GINA) report supports a rescue approach that treats both symptoms and inflammation together.
  • Now, with AIRSUPRA available we can provide patients, especially those on maintenance therapy, another rescue option for managing their breakthrough symptoms.

Multicultural & Inclusive Marketing: Why Retailers Must Embrace the Multicultural Majority

Retrieved on: 
Tuesday, October 17, 2023
Salbutamol, Asthma, CSR, Organization, Culture, Ageing, Procter & Gamble, DEIB, FDA, Workforce, Diversity, Corporate social responsibility, Growth, Nike, Marketing, Social commerce, Management, Sales, Creative industries

WINDERMERE, Fla., Oct. 17, 2023 /PRNewswire-PRWeb/ -- 2020 marked the official year that the generation of Americans aged 17 and under was a multicultural majority, but the actual shift happened between census years.(1) This means Americans 35 and under reached a multicultural majority in 2023, and by 2028 Americans under 50 will have as well.(2) Retailers now have to reach a more diverse audience more effectively, and accurate data is vital to successful multicultural and inclusive marketing. Derek Chew, CEO of Fullmoon Digital, explains that it is more critical than ever for companies to understand their audience through a multicultural lens.

Key Points: 
  • Derek Chew, CEO of Fullmoon Digital, explains how multicultural and inclusive marketing go hand-in-hand with DEIB to create winning commerce strategies.
  • (1) This means Americans 35 and under reached a multicultural majority in 2023, and by 2028 Americans under 50 will have as well.
  • (2) Retailers now have to reach a more diverse audience more effectively, and accurate data is vital to successful multicultural and inclusive marketing.
  • (5) However, while CSR and DEIB benefit brands and customers, they are not the same as multicultural and inclusive marketing.

Global Bronchodilators Market Report 2023: Sector is Expected to Reach $28.75 Billion by 2030 at a CAGR of 3.29% - ResearchAndMarkets.com

Retrieved on: 
Wednesday, June 14, 2023
Pharmaceutical, Health, Medical Devices, Real, COPD, Budesonide, Smoker, Asthma, Salbutamol, Global Initiative, Inhaler, American Lung Association, GOLD, SABA, AstraZeneca, Cipla, ICS, LMIC, Chronic obstructive pulmonary disease, Incidence, Patient, Risk, Growth, WHO, Global Initiative for Chronic Obstructive Lung Disease, FDA, Social media, Pharmaceutical industry, Teva

The demand for bronchodilators is growing significantly, owing to the increasing incidence of respiratory disorders.

Key Points: 
  • The demand for bronchodilators is growing significantly, owing to the increasing incidence of respiratory disorders.
  • The surging number of smokers is increasing the population with a heightened risk of lung conditions such as asthma and COPD.
  • For instance, as per WHO in 2021, there are over 1.3 billion smokers globally with 80% of them situated in LMIC's.
  • This creates a need for persistent use of bronchodilators in patients, thereby, accelerating the demand for bronchodilators.

Phil and Teva Pharmaceuticals Launch New Program to Improve Access to the Digihaler® Family of Inhalers to Support Asthma Management

Retrieved on: 
Tuesday, June 6, 2023
Software, Pharmaceutical, Data Management, IOT (Internet of Things), Apps, Applications, Technology, Medical Devices, Health Technology, Health Insurance, Biotechnology, Wearables, Mobile Technology, Practice Management, Health, Hypersensitivity, Anti-inflammatory, Salbutamol, Angioedema, Rash, Pain, Contraindication, Prednisone, Adrenal insufficiency, Digital health, Patient, Risk, Common, SVP, Arrhythmia, Hyperthyroidism, Wheeze, Physician, Urinary tract infection, Innovation, ICS, Measles, Hypertension, Vomiting, Back pain, System, Anaphylaxis, Trauma, Death, Moyamoya disease, Sinusitis, Allergy, Fungus, Fever, Eye, Hypokalemia, Record, Parasitism, Chickenpox, Medicine, LABA, Hives, Tuberculosis, Immune system, Milk, Heart rate, Bronchoconstriction, Blood pressure, Infection, Teva Pharmaceuticals, Gastroenteritis, Partnership, Diabetes, Tricyclic, Simplex, EMR, Fatality, Respiratory disease, Inc., Itch, Lactose, Bronchospasm, Immunosuppression, Fluticasone/salmeterol, Pharmaceutical industry, Generic drug, Vaccine, Medical device, Asthma

The goal of Phil and Teva Pharmaceuticals’ partnership is to help enable patients to receive and refill their Digihaler medication quickly, easily and affordably.

Key Points: 
  • The goal of Phil and Teva Pharmaceuticals’ partnership is to help enable patients to receive and refill their Digihaler medication quickly, easily and affordably.
  • Using the PhilRx Patient Access Platform, patients can fill their prescription, review prescription records and obtain assistance navigating insurance benefits.
  • The PhilRx Patient Access Platform provides end-to-end visibility into the entire prescription life cycle, starting when the physician writes the prescription.
  • Physicians can select the PhilRx Patient Access Platform directly from an electronic medical record (EMR) to submit a prescription for a Digihaler product.

Nephron To Produce 0.5% Albuterol 5 mL, Alleviating Nationwide Shortage

Retrieved on: 
Wednesday, May 31, 2023
Patient, Hospital, FDA, Health, Salbutamol, Multimedia, IV, Pharmaceutical industry, Nursing, Nephron

WEST COLUMBIA, S.C., May 31, 2023 /PRNewswire/ -- Nephron Pharmaceuticals Corporation today announced that preservative-free 0.5% Albuterol Sulfate Inhalation Solution is available now in a 25 mg/5 mL pre-filled vial.

Key Points: 
  • WEST COLUMBIA, S.C., May 31, 2023 /PRNewswire/ -- Nephron Pharmaceuticals Corporation today announced that preservative-free 0.5% Albuterol Sulfate Inhalation Solution is available now in a 25 mg/5 mL pre-filled vial.
  • Nephron received FDA approval for Albuterol 0.5% 0.5 mL in 2001 and now provides millions of doses per year to patients nationwide.
  • In addition to Albuterol 0.5% 0.5 mL produced by Nephron, Nephron 503B Outsourcing Facility is now offering a larger fill volume of this essential product directly to hospitals and medical facilities, in an effort to alleviate the nationwide shortage.
  • A West Columbia, S.C.-based company, Nephron develops and produces safe, affordable generic inhalation solutions and suspension products.

The Ritedose Corporation Begins production of Drug to Alleviate National Medication Shortage

Retrieved on: 
Tuesday, April 25, 2023
COPD, Akorn, Abbreviated New Drug Application, Asthma, Chastain, Inhalation, Chronic obstructive pulmonary disease, Hospital, Salbutamol, CGMP, Patient, COVID-19 pandemic, ANDA, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, BFS, Food, Pharmaceutical industry

COLUMBIA, S.C., April 25, 2023 /PRNewswire/ -- The Ritedose Corporation (Ritedose), an industry leader in pharmaceutical development, aseptic cGMP manufacturing and 503B outsourcing solutions, has begun production of a particular form of Albuterol Sulfate that the FDA has listed in short supply in the United States. It will be available in May.

Key Points: 
  • In March, the U.S. Food and Drug Administration (FDA) announced a drastic downturn in the nation's supply of Albuterol Sulfate (0.5% Inhalation Solution).
  • "Major shifts in the market's ability to meet demand has driven our rapid response," said Jody Chastain, CEO of The Ritedose Corporation.
  • "We are all about patient safety and reliability—the U.S. can count on us to step-up and solve the drug shortage gap of Albuterol Sulfate."
  • For long-term supply chain continuity, Ritedose will be submitting an additional Abbreviated New Drug Application (ANDA) in other container sizes to meet supply demands.

PT027 Recommended by FDA Advisory Committee as New Rescue Treatment for Asthma

Retrieved on: 
Wednesday, November 9, 2022
Biotechnology, Pharmaceutical, General Health, Health, FDA, Health Technology, Clinical Trials, Other Health, Online, COPD, Safety, Research, Risk, Death, Link, Efficacy, Journal of Asthma and Allergy, Company, ADULT, Salbutamol, Conference, Papis Loveday, Inhaler, Risk factor, AstraZeneca, Dermatology, Spirometry, Internet, Jean-Jacques Bourdin, MDI, ICS, Science, Diagnosis, Global Initiative for Asthma, Patient, B93, Observational study, Ageing, ERS, BDA, SCS, Chronic lung disease, Week, Biopharmaceutical, Clare Lloyd, CDC, Veni, vidi, vici, Gastroenterology, Hospital, Atmosphere, Medicine, Clinical trial, Growth, NDA, Immunology, AES, ClinicalTrials.gov, Child, Rheumatology, Nature Research, Mortality, Protein Data Bank (file format), Budesonide, ID, Disease, Thomas Ford Chipp, Metabolism, Pharmaceutical industry, Silviculture, Asthma, FEV1, Oncology, Common

PT027 is a potential first-in-class SABA/ICS rescue treatment for asthma in the US, to be taken as needed.

Key Points: 
  • PT027 is a potential first-in-class SABA/ICS rescue treatment for asthma in the US, to be taken as needed.
  • In March 2018, AstraZeneca and Avillion signed an agreement to advance PT027 through a global clinical development program for the treatment of asthma.
  • Following the successful approval of PT027, AstraZeneca has the option, upon certain financial payments, to commercialize the medicine in the US.
  • The Company aims to transform the treatment of asthma and COPD by focusing on earlier biology-led treatment, eliminating preventable asthma attacks, and removing COPD as a top-three leading cause of death.